Cite
MLA Citation
Annette E. Hay et al.. “A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.” Leukemia & lymphoma, vol. 57, no. 6, n.d., pp. 1463–1466. http://access.bl.uk/ark:/81055/vdc_100034281744.0x00003e